Clinical Trial Update: Study of Curcumin, Vorinostat, and Sorafenib [Phase 1]

View source ↗

Summary

A Phase 1 study of curcumin, vorinostat, and sorafenib for advanced cancers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Curcumin (curcumin)
• Nexavar (Sorafenib)
• Zolinza (vorinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancers | Phase 1 | Status: WITHDRAWN